Physician profile
Ryan M Biggers
NPI 1194723395
$2,799.28
in general payments reported to CMS, 2019-2025
24 companies · $673 in 2025
The $673 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $487 · 2023: $873 · 2024: $766 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,312.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $678.14 | 2022-2025 | Qulipta, Ubrelvy, Linzess |
| Novo Nordisk INC | $408.68 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $275.30 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $218.53 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $206.76 | 2022-2025 | |
| Glaxosmithkline, LLC. | $151.31 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.44 | 2022-2025 | Jardiance |
| Amgen INC. | $124.36 | 2023-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $91.11 | 2024-2025 | |
| Dexcom, INC. | $78.45 | 2022-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $65.87 | 2022-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.43 | 2023-2025 | Xifaxan |
| Edwards Lifesciences Corporation | $41.62 | 2022 | |
| Antares Pharma, INC. | $39.98 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Exact Sciences Corporation | $39.79 | 2024-2025 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $33.44 | 2023 | Quviviq |
| Almatica Pharma LLC | $32.16 | 2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Nestle Healthcare Nutrition INC. | $24.04 | 2022 | |
| Bausch Health US, LLC | $20.19 | 2024 | Aplenzin |
| Sumitomo Pharma America, INC. | $19.99 | 2024 | Gemtesa |
| Astellas Pharma US INC | $18.35 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.30 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.56 | 2023 | |
| Paratek Pharmaceuticals, INC. | $13.48 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Biggers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.